Close

New horizon 2020 B-SMART project begins developing therapies for degenerative pathologies of the Nervous System that relies on RNA

06 February 2018

  • The new European B-SMART research project uses nanopharmaceuticals containing RNA for the treatment of Alzheimer's and spinal and bulbar muscular atrophy (SBMA)
  • Innovative RNA transport systems based on nanotechnology aimed at removing the primary etiology of the pathology
  • B-SMART brings together renowned international experts, from 9 academic institutions and industrial partners, coordinated by the Medical Center of the University of Utrecht
  • The European Commission invests € 6 million over the next 5 years

Aprilia, 6 February 2017 - Neurodegenerative diseases such as Alzheimer's affect more than 7 million people in Europe - a figure that will duplicate every 20 years as the population ages and put a strain on European health care systems. In spite of this, few treatments are available for this group of diseases. The drugs available today only suppress the symptoms or delay the progression of the disease but do not remove the causes. Furthermore, no drug has been approved for Alzheimer's in the last 5 years.

Nanomedicine can make a difference by making new therapeutic options available that allow drugs to reach the site of action in the brain. This is why the B-SMART multinational research project aims to develop a therapy based on RNA with the aim of directly affecting the cause of the disease instead of its symptoms.

The project is funded for the next 5 years by the European Commission under the Horizon 2020 framework program with a total budget of € 6 million.

"Transferring therapeutic RNA to the brain by crossing the blood-brain fluid barrier is an original research approach," said Prof. Raymond Schiffelers at the University of Utrecht Medical Center and coordinator of B-SMART. "Identifying a new window for the transport of RNA to the brain will allow the development of therapies aimed at the etiology not only for Alzheimer's, but also for other diseases".

The consortium will work to develop specific nanocarriers to protect RNA from enzymatic degradation and to transport it to the human brain. Crossing the blood-brain barrier requires specific ligands for transport, which will be made up of "nanocorps", i.e. antibodies made up of only the heavy and therefore smaller and more stable chains of conventional antibodies. The modular transport system will be tested for safety and efficacy both in vitro and in vivo. To improve the production of nanomedicine, B-SMART has chosen a method based on the use of a microfluidic system, independent of the operator and easily scalable.

Within this ambitious project, the Process Development Group of the Italian Biochemical Institute G. Lorenzini, with consolidated experience in aseptic dosage and in the study of the production processes of injectable organic medicinal products, is strongly motivated to provide innovative solutions for the industrial scaling-up of the production process, in order to meet cGMP quality standards and regulatory authorities' requests.

B-SMART brings together an international team of renowned experts from 9 institutions with consolidated experience in their respective fields of specialization. B-SMART partners are involved in numerous national and international research programs in close cooperation with industry at all stages of the project to bridge the gap between research and industry and enable the timely exploitation of search results.

B-SMART officially started the activity with the first meeting held in Utrecht on February 1st and 2nd 2017.

B-SMART PARTNERS

Netherlands
University Medical Center Utrecht 20 Med Therapeutics BV

Spain
University of Santiago de Compostela

Belgium
VIB

United Kingdom
The Chancellor, Masters and Scholars of the University of Oxford
Malvern Instruments Ltd

Italy
Italian Biochemical Institute Giovanni Lorenzini SpA

Norway
Stiftelsen SINTEF

Germany
EURICE - European Research and Project Office GmbH

PROJECT DETAILS

Name: B-SMART Brain-specific, Modular and Active RNA Therapeutics
Start date: 2017-01-01 - Duration: 60 months - Budget: € 6 million - Coordination: Universitair Medisch Centrum Utrecht - Phone: +31 88 7556512            

CONTACT

Coordinator: University Medical Center Utrecht - Prof. Raymond Schiffelers - Email: R.Schiffelers@umcutrecht.nl - Phone: +31 88 7556512
Project Management: EURICE - European Research and Project Office GmbH - Corinna Hahn - Email: c.hahn@eurice.eu - Phone: +49 681 95 923362 www.B-SMART-PROJECT.eu

Latest news

undefined

REVER3MAB: "An ambitious project for the development of an innovative biological drug"?

IBI collaborates in the development of an innovative biological drug to revert resistance to conventional cancer treatments: project: REVER3MAB (EU, State and Region)

Read all
undefined

Seguiamo i farmaci fino a voi

Cinquanta milioni di investimento digitale e un forte impegno nella tracciabilità dei prodotti

Read all
undefined

Ibi partecipa all'iniziativa UniCredit 4 Growth

Read all

Thank you

We sent you an email. To activate the newsletter click on the link you will find in the message, thank you!

Sign up for the newsletter


Dichiarazione in merito al GDPR (Regolamento Generale Protezione dei Dati)

In caso di sottoscrizione Newsletter dovrai confermare l’iscrizione per mezzo di mail di conferma inviata all’indirizzo inserito. In tal caso il trattamento prevede:

la profilazione dell’utente in gruppi, status, preferenze secondo quanto indicato e dedotto dalle informazioni inviate tramite il form o successiva autonoma profilazione.
l’utilizzo del dato per l’invio di comunicazione a mezzo digitale (email, whatsapp) e non (cartaceo) avente scopo informativo/commerciale.
l'utilizzo della mail per la generazione di campagne marketing e informative personalizzate, digitali e non.

Cancel
CHIUDI


Private area


Log in to restricted area


Registration


Notice on the treatment of personal data

Dear visitor, in the following sections we will describe how the reserved area of the www.ibi-lorenzini.it website is managed as far as processing personal data of users. The notice is issued pursuant to art. 13 of EU Regulation 679/2016 (hereinafter also the Regulation) on the protection of natural persons with regard to the processing of personal data and on the free movement of such data, and applies to those who interact with the website of Istituto Biochimico Italiano Giovanni Lorenzini S.p.A. (hereinafter I.B.I.), which can be accessed at the following address: www.ibi-lorenzini.it, the opening page of the official I.B.I. website. The notice only applies to the I.B.I. website. It does not apply to any other websites that the user may access through links.

  1. The processing of the personal data that you supply, which are also used for the creation of your user profile, and which will be included in the “Doctors’ Details” database, has the following purposes:
  • carry out medical sales related activities for drugs for human consumption. Istituto Biochimico Italiano Giovanni Lorenzini S.p.A. and Ibigen S.r.l., part of the same company group (hereinafter also Ibigen Group), carry out such activities in compliance with the provisions of the current regulations, with particular, but not exclusive, attention to Italian Legislative Decree no. 219 of 24.04.2006 and subsequent modifications. In view of the objectives of the Ibigen Group, it is important to point out that the processing activities do not deal with any special data. The supply of the data for the medical sales activities is necessary, and failure to provide consent will make it impossible for us to fulfil the above objectives;

  • forwarding of invitations or information on congresses, conferences, seminars, communications on initiatives promoted or sponsored by the Ibigen group, regular or occasional publications, information on new products, methods and services. Such activities are carried out by e-mail, fax, SMS, normal post or telephone. The supply of the data for such purposes is optional, and failure to supply them will result in the information not being forwarded.

  1. As far as the creation of your profile on our website, we remind you that your password is strictly confidential and should not be disclosed.
  2. Your data will not be disclosed, but may be shared with individuals, companies, associations or professional studios providing support or consultancy services to the Ibigen Group, the medical sales representative network, our suppliers and any sub-suppliers - from time to time entrusted with activities connected with the above objectives -, mailing or statistical survey companies, or companies for the forwarding of scientific documentation, and individuals authorised to access the data by law and/or pursuant to secondary regulations.
  3. Such people may only acquire knowledge of your personal data for the above mentioned purposes.
  4. The Owners of the Treatment (Data Controllers) are the two companies of the Ibigen Group with legal headquarters at Via Fossignano no. 2, Aprilia (LT), Italy.
  5. Personal data are processed using manual and automated means, for the time necessary for reaching the objectives for which they were collected. Special safety measures are in place to avoid data loss, unlawful or incorrect use and unauthorised access.
  6. Lastly, we also inform you that you can at any time exercise the rights contemplated by the Regulation, and in particular request access to the data, their correction, update and block, or you can withdraw your consent, or request the limitation of the processing or the cancellation of the data. As data subject, you also have the right to issue a complaint with the relevant control Authority. Such rights may be exercised in writing to the following e-mail address: info@ibi-lorenzini.com.
  7. The Data Protection Officer may be contacted at the following e-mail address: dpo_ibi@protectiontrade.it

* Required fields

Cancel